Leukeran

chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as oral tablets for oral use. It is employed in the treatment of chronic lymphocytic leukemia and certain Hodgkin’s and non‑Hodgkin’s lymphomas in adult patients.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Chlorambucil is used primarily in hematologic malignancies that respond to alkylating chemotherapy.

Chronic lymphocytic leukemia (CLL): reduces leukemic cell proliferation and prolongs remission. Hodgkin’s lymphoma: contributes to disease control in early‑stage disease. Low‑grade non‑Hodgkin’s lymphoma: achieves tumor reduction and symptom relief.

Chlorambucil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during therapy. - Bone marrow suppression: leukopenia, anemia, and thrombocytopenia. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: reversible hair loss. - Loss of appetite: reduced food intake.

Serious or Rare Side Effects: - Severe myelosuppression: profound neutropenia increasing infection risk. - Secondary malignancies: potential development of new cancers. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hemorrhagic cystitis: bladder inflammation with bleeding. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Chlorambucil therapy, consider the following precautions.

Monitor blood counts: perform regular complete blood count to detect myelosuppression. Assess renal function: adjust use in patients with impaired kidney function. Avoid live vaccines: immunosuppression may reduce efficacy. Pregnancy caution: use only if benefits outweigh risks. Concomitant myelosuppressive therapy: limit combined use to reduce severe bone marrow toxicity. Store at ambient temperature: keep in original container, protect from moisture and light.

Chlorambucil can interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increase risk of severe bone marrow suppression. - Radiation therapy: additive cytotoxic effects may exacerbate tissue damage. - Live vaccines: reduced vaccine efficacy and increased infection risk.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): may lower chlorambucil plasma levels. - Anticoagulants (e.g., warfarin): may enhance bleeding tendency.